|1.||Balena, Raffaella: 6 articles (03/2013 - 07/2009)|
|2.||Boldrin, Mark: 4 articles (03/2013 - 07/2009)|
|3.||Kanitra, Linda: 2 articles (02/2013 - 07/2012)|
|4.||Woloschak, Michael: 2 articles (12/2012 - 07/2012)|
|5.||Tobalina, L: 2 articles (04/2011 - 08/2010)|
|6.||Sewing, S: 2 articles (04/2011 - 08/2010)|
|7.||Sebokova, E: 2 articles (04/2011 - 08/2010)|
|8.||Bénardeau, A: 2 articles (04/2011 - 08/2010)|
|9.||Migliorini, C: 2 articles (04/2011 - 08/2010)|
|10.||Sturm-Pellanda, Carolina: 1 article (11/2015)|
|1.||Body Weight (Weight, Body)
08/01/2010 - "A significant reduction in body weight gain was noticed by day 8, and continued until the end of the study when body weight was approximately 7% lower in rats treated with taspoglutide compared to vehicle. "
02/01/2015 - "The objective of this study was to develop a quantitative model to delineate the net efficacy of taspoglutide on body weight (WT) loss from the response of placebo in type 2 diabetes patients, and further find pharmacodynamic potency of taspoglutide for half of maximum reduction response of WT. Several PD data about taspoglutide treatments for type 2 diabetes patients were digitalized from the published papers. "
02/01/2015 - "The efficacy of placebo-adjusted taspoglutide on body weight reduction in clinical trials."
02/01/2015 - "The longitudinal MBMA could be utilized to quantitatively describe the efficacy of taspoglutide on body weight loss and may lead to a clinical guideline for treatment of type 2 diabetes patients in the future."
03/01/2012 - "In drug-naive patients, once-weekly taspoglutide improved glycemic control, reduced body weight, and was generally well tolerated."
|2.||Weight Loss (Weight Reduction)
02/01/2013 - "Weight loss at week 24 was significantly greater with taspoglutide than placebo (LSMean, -3.16 vs. -1.85 kg; P < 0.01). "
02/01/2013 - "In obese patients with T2DM, once-weekly taspoglutide provided the combined benefits of glycemic control and weight loss."
11/01/2015 - "Once-weekly subcutaneous injections with taspoglutide demonstrated meaningful antihyperglycemic and weight loss effects in patients with type 2 diabetes. "
07/01/2012 - "With taspoglutide 10 mg and 20 mg vs. placebo, significantly greater reductions in fasting plasma glucose [-1.87 mmol/liter (-34 mg/dl) and -2.12 mmol/liter (-38 mg/dl) vs. -0.57 mmol/liter (-10 mg/dl); P < 0.0001], improvements in homeostasis model assessment of β-cell function score (20.65 and 33.52 vs. -2.03; P < 0.0001), and significant weight loss (-0.64 kg and -1.04 kg vs. 0.59 kg; P < 0.01) were observed. "
12/01/2012 - "Taspoglutide demonstrated better efficacy on glycemic control and weight loss than sitagliptin, but a high incidence of adverse events led to high discontinuation rates. "
|3.||Type 2 Diabetes Mellitus (MODY)
12/01/2012 - "Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)."
07/01/2012 - "This study assessed the efficacy and safety of once-weekly taspoglutide in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone compared with placebo. "
07/01/2012 - "Taspoglutide provided glycemic control with weight loss as add-on therapy to metformin plus pioglitazone for inadequately controlled type 2 diabetes mellitus."
01/01/2012 - "A MEDLINE search (1966-August 2011) was conducted using the following key words: type 2 diabetes mellitus, glucagon-like peptide-1 agonists once weekly, glucagon-like peptide-1 agonists, exenatide LAR, albiglutide, and taspoglutide. "
01/01/2012 - "To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM). "
05/01/2010 - "There have been no reports to date of development of acute pancreatitis in patients taking albiglutide or taspoglutide. "
05/01/2010 - "Phase 2 and 3 clinical trials evaluating exenatide, liraglutide, albiglutide, and taspoglutide that discussed treatmentrelated adverse effects as well as FDA-reviewed case reports of pancreatitis in patients taking these same therapies were included. "
03/01/2014 - "This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide."
05/01/2010 - "Key search terms included type 2 diabetes mellitus, pancreatitis, incretins, exenatide, liraglutide, albiglutide, and taspoglutide. "
11/01/2015 - "Regardless of a pronounced period effect, relative bioavailability of taspoglutide was different across injection sites, with the lowest exposure and incidence of nausea and vomiting seen after administration in the abdomen. "
11/01/2015 - "Overall, taspoglutide was well tolerated by most subjects in all 3 injection sites, with a lower incidence of nausea and vomiting when injected in the abdomen. "
02/01/2013 - "Nausea and vomiting were the most common AEs associated with taspoglutide, but tended to be transient and generally mild or moderate. "
07/01/2012 - "Adverse events were generally mild to moderate; the most frequent adverse events with taspoglutide 10 mg, taspoglutide 20 mg, and placebo were nausea (35, 44, and 10%), vomiting (21, 24, and 2%), and injection site reactions (24, 24, and 5%). "
03/01/2013 - "More adverse events with taspoglutide 10 and 20 mg than exenatide developed over time (nausea in 53, 59, and 35% and vomiting in 33, 37, and 16%, respectively). "
|2.||Glucagon-Like Peptide 1 (GLP 1)